PL2696878T3 - Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej - Google Patents

Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej

Info

Publication number
PL2696878T3
PL2696878T3 PL12717824T PL12717824T PL2696878T3 PL 2696878 T3 PL2696878 T3 PL 2696878T3 PL 12717824 T PL12717824 T PL 12717824T PL 12717824 T PL12717824 T PL 12717824T PL 2696878 T3 PL2696878 T3 PL 2696878T3
Authority
PL
Poland
Prior art keywords
sapacitabine
decitabine
combination
myeloid leukemia
acute myeloid
Prior art date
Application number
PL12717824T
Other languages
English (en)
Polish (pl)
Inventor
Judy Chiao
Original Assignee
Cyclacel Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1106339.3A external-priority patent/GB201106339D0/en
Priority claimed from GBGB1117693.0A external-priority patent/GB201117693D0/en
Priority claimed from GBGB1121105.9A external-priority patent/GB201121105D0/en
Application filed by Cyclacel Limited filed Critical Cyclacel Limited
Publication of PL2696878T3 publication Critical patent/PL2696878T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12717824T 2011-04-14 2012-04-13 Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej PL2696878T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1106339.3A GB201106339D0 (en) 2011-04-14 2011-04-14 Combination
GBGB1117693.0A GB201117693D0 (en) 2011-10-13 2011-10-13 Combination
GBGB1121105.9A GB201121105D0 (en) 2011-12-08 2011-12-08 Combination
PCT/GB2012/050815 WO2012140436A1 (en) 2011-04-14 2012-04-13 Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
EP12717824.2A EP2696878B1 (en) 2011-04-14 2012-04-13 Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia

Publications (1)

Publication Number Publication Date
PL2696878T3 true PL2696878T3 (pl) 2020-01-31

Family

ID=46022492

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12717824T PL2696878T3 (pl) 2011-04-14 2012-04-13 Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej

Country Status (7)

Country Link
US (2) US10226478B2 (OSRAM)
EP (2) EP2696878B1 (OSRAM)
JP (1) JP6093755B2 (OSRAM)
ES (1) ES2743691T3 (OSRAM)
HU (1) HUE046177T2 (OSRAM)
PL (1) PL2696878T3 (OSRAM)
WO (1) WO2012140436A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012140436A1 (en) 2011-04-14 2012-10-18 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
US9872874B2 (en) 2012-05-15 2018-01-23 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
EP3074018A1 (en) * 2013-11-27 2016-10-05 Oncoethix GmbH Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2019081951A1 (en) 2017-10-27 2019-05-02 Cyclacel Limited DOSAGE REGIME
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
FI105556B (fi) 1991-09-30 2000-09-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta
US5824984A (en) 1997-03-31 1998-10-20 Morrow; John A. Portable electric wire cutter
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US6835185B2 (en) 1998-12-21 2004-12-28 Micrus Corporation Intravascular device deployment mechanism incorporating mechanical detachment
US6462063B1 (en) 2000-02-04 2002-10-08 Fibrogen, Inc. C-proteinase inhibitors
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2410579C (en) 2000-05-26 2010-04-20 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses
DE60139689D1 (de) 2000-06-22 2009-10-08 Univ Iowa Res Found Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
AU2002230385A1 (en) 2000-09-25 2002-04-15 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
KR20090089922A (ko) 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
JP2004533805A (ja) 2000-10-18 2004-11-11 フアーマセツト・リミテツド 疾患細胞中の核酸の多重定量
JP2004538247A (ja) 2000-12-08 2004-12-24 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー セミカルバジド及びサイクリン依存キナーゼ阻害剤
US6908906B2 (en) 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
JP3748536B2 (ja) 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
US6676692B2 (en) 2001-04-27 2004-01-13 Intek Technology L.L.C. Apparatus for delivering, repositioning and/or retrieving self-expanding stents
ES2333412T3 (es) 2001-05-25 2010-02-22 Bristol-Myers Squibb Company Derivados de hidantoina como inhibidores de metaloproteinasas de matriz.
US6949558B2 (en) 2001-11-07 2005-09-27 Yale University Enhancement of taxane-based chemotherapy by a CDK1 antagonist
US7137993B2 (en) 2001-12-03 2006-11-21 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
US7569554B2 (en) 2003-05-16 2009-08-04 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
US20050014716A1 (en) 2003-05-21 2005-01-20 Wang Jin Wei Pancreatic cancer treatment
GB0328180D0 (en) 2003-12-04 2004-01-07 Cyclacel Ltd Combination
US20090047365A1 (en) 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
US20060212899A1 (en) 2005-03-17 2006-09-21 Ryan Steelberg System and method for broadcast tagging
GB0523041D0 (en) 2005-11-11 2005-12-21 Cyclacel Ltd Combination
GB0526419D0 (en) 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0609530D0 (en) 2006-05-12 2006-06-21 Cyclacel Ltd Combination
JP2009543768A (ja) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド 医薬組み合わせ
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP5852309B2 (ja) * 2007-04-25 2016-02-03 サイクラセル リミテッド 増殖性疾患を治療するためのサパシタビンの使用
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
CN101185629A (zh) 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的地西他滨缓释剂
GB0808357D0 (en) 2008-05-08 2008-06-18 Cyclacel Ltd Process
US8530445B2 (en) 2008-06-09 2013-09-10 Cyclacel Limited Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine
WO2012140436A1 (en) 2011-04-14 2012-10-18 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia

Also Published As

Publication number Publication date
US20140094428A1 (en) 2014-04-03
EP3560501A1 (en) 2019-10-30
US10226478B2 (en) 2019-03-12
EP2696878A1 (en) 2014-02-19
JP2014510780A (ja) 2014-05-01
US20190314396A1 (en) 2019-10-17
EP2696878B1 (en) 2019-07-10
ES2743691T3 (es) 2020-02-20
HUE046177T2 (hu) 2020-02-28
WO2012140436A1 (en) 2012-10-18
JP6093755B2 (ja) 2017-03-08

Similar Documents

Publication Publication Date Title
IL323574A (en) Pertuzumab and trastuzumab for use in the treatment of
IL274206A (en) MASP-2 suppressors for use in the treatment of radiation heredity syndrome
GB2509271B (en) Patient-specific sacroiliac guides and associated methods
IL236962B (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
PL2928431T3 (pl) Wyroby chłonne z kanałami
PL2928430T3 (pl) Wyroby chłonne z kanałami
IL233948B (en) A smoking item that includes dual heat conductive components
GB201313257D0 (en) MALDimaging and ion guide
ZA201401527B (en) Improvements in lockers
PL2780332T3 (pl) Morfolinylobenzotriazyny do zastosowania w terapii rakowej
IL229243A0 (en) Complementary factor b analogs and their uses
EP2621516A4 (en) INTERFERON BETA FOR USE AS MONOTHERAPY OR IN COMBINATION WITH OTHER CANCER THERAPIES
PL2696878T3 (pl) Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
IL238606B (en) CD44v6-derivative peptides for the treatment of cancer metastases
ZA201306442B (en) Chop gate and nozzle
ZA201406172B (en) Compounds and methods for treating leukemia
ZA201402151B (en) Romidepsin and 5- azacitidine for use in treating lymphoma
HUE046993T2 (hu) Készítmény radioterápia és kemoterápia által okozott leukopenia megelõzésében és kezelésében történõ alkalmazásra
PL2769727T3 (pl) Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworów
PL2694050T3 (pl) Tapentadol do stosowania w leczeniu bólu związanego z nerwobólami nerwu trójdzielnego
EP2854774A4 (en) METHODS OF TREATING INSOMNIA
EP2714061A4 (en) AGGREGATE AND TEA TO IMPROVE AUTISM
ZA201406351B (en) Combination treatment (eg. with abt-072 or abt -333) of daaas for use in theating hvc
GB201205947D0 (en) Use of acylated shives in composites